Vaxcyte (NASDAQ:PCVX) COO Sells $212,340.39 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 3,477 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $61.07, for a total value of $212,340.39. Following the completion of the sale, the chief operating officer owned 155,041 shares in the company, valued at approximately $9,468,353.87. The trade was a 2.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total value of $126,742.50.

Vaxcyte Stock Performance

Shares of PCVX opened at $61.16 on Friday. The stock has a 50-day simple moving average of $58.22 and a 200-day simple moving average of $56.20. The stock has a market capitalization of $9.10 billion, a PE ratio of -8.02 and a beta of 1.22. Vaxcyte, Inc. has a 1 year low of $30.81 and a 1 year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same period last year, the company earned ($1.22) EPS. Analysts predict that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PCVX shares. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

Institutional Trading of Vaxcyte

Several institutional investors have recently modified their holdings of the stock. NEXTBio Capital Management LP purchased a new position in shares of Vaxcyte during the fourth quarter worth about $4,406,000. Norges Bank purchased a new stake in shares of Vaxcyte in the 4th quarter valued at about $56,703,000. Eventide Asset Management LLC boosted its position in shares of Vaxcyte by 141.8% in the 4th quarter. Eventide Asset Management LLC now owns 917,115 shares of the company’s stock valued at $42,313,000 after purchasing an additional 537,785 shares during the period. Elmind Capital LP acquired a new stake in shares of Vaxcyte in the 4th quarter valued at about $13,450,000. Finally, Candriam S.C.A. purchased a new position in Vaxcyte during the 1st quarter worth approximately $18,306,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.